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ImOBJECTIVES This study aimed to assess the impact of thrombus aspiration on mortality in patients with ST-segment
elevation myocardial infarction treated with primary percutaneous coronary intervention (PCI).
BACKGROUND The clinical effect of routine intracoronary thrombus aspiration before primary PCI in patients with
ST-segment elevation myocardial infarction is uncertain.
METHODS We undertook an observational cohort study of 10,929 ST-segment elevation myocardial infarction patients
from January 2005 to July 2011 at 8 centers across London, United Kingdom. Patients’ details were recorded at the time
of the procedure into local databases using the British Cardiac Intervention Society PCI dataset. Primary outcome was all-
cause mortality at a median follow-up of 3.0 years (interquartile range: 1.2 to 4.6 years).
RESULTS In our cohort, 3,572 patients (32.7%) underwent thrombus aspiration during primary PCI. Patients who had
thrombus aspiration were younger, had lower rates of previous myocardial infarction but were more likely to have poor
left ventricular function. Procedural success rates were higher (90.9% vs. 89.2%; p ¼ 0.005) and in-hospital major
adverse cardiac event rates were lower (4.4% vs. 5.5%; p ¼ 0.012) in patients undergoing thrombus aspiration. However,
Kaplan-Meier analysis demonstrated no signiﬁcant difference in mortality rates between patients with and without
thrombus aspiration (14.8% aspiration vs. 15.3% PCI only; p ¼ 0.737) during the follow-up period. After multivariate Cox
analysis (hazard ratio [HR]: 0.89, 95% conﬁdence interval [CI]: 0.65 to 1.23) and the addition of propensity matching
(HR: 0.85 95% CI: 0.60 to 1.20) thrombus aspiration was still not associated with decreased mortality.
CONCLUSIONS In this cohort of nearly 11,000 patients, routine thrombus aspiration was not associated with a
reduction in long-term mortality in patients undergoing primary PCI, although procedural success and in-hospital major
adverse cardiac event rates were improved. (J Am Coll Cardiol Intv 2015;8:575–84) © 2015 by the American College of
Cardiology Foundation.m the *Department of Cardiology, Barts Health National Health Service (NHS) Trust, London, United Kingdom; yDepartment of
rdiology, King’s College Hospital, King’s College Hospital NHS Foundation Trust, London, United Kingdom; zDepartment
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576M echanical reperfusion with pri-mary percutaneous coronary in-tervention (PPCI) is the optimal
treatment strategy for patients with ST-
segment elevation myocardial infarction
(STEMI) (1). During PPCI, embolization of
thrombus and plaque fragments into the
distal coronary artery bed may lead to micro-
vascular obstruction and reduced ﬂow asso-
ciated with failure to achieve restoration of
microvascular perfusion, and this has been
associated with an increase in mortality
(2,3). Removing the thrombus prior to PCI,
with the use of thrombectomy devices could
prevent distal embolization, improve micro-
vascular perfusion, and improve outcomesafter STEMI treated with PPCI. Both the European
Society of Cardiology and American College of Car-
diology/American Heart Association guidelines
recommend that coronary artery thrombus aspiration
should be considered as an adjunctive therapy during
PPCI for STEMI (4,5).SEE PAGE 585These recommendations (IIa) are mainly based on
a single study, the TAPAS (Thrombus Aspiration
During Percutaneous Coronary Intervention in Acute
Myocardial Infarction Study). This was a single-
center trial involving 1,071 patients, which demon-
strated not only an improvement in the primary
outcome of myocardial blush grade but a nearly 50%
reduction in mortality at 1 year (6,7). However, since
TAPAS, the evidence supporting the beneﬁt of
thrombus aspiration on clinical outcomes is less
clear (3,8–10). The recent publication of the largest
randomized trial of thrombus aspiration, TASTE
(Thrombus Aspiration During ST-Segment Elevation
Myocardial Infarction), which randomized over 7,000
patients to thrombus aspiration or PCI alone, sug-
gested that routine aspiration does not reduce either
30-day or 1-year mortality in patients undergoing
PPCI (11,12).
The aim of this study was to describe the impact of
thrombus aspiration on post-procedural outcomes,
post-PPCI TIMI (Thrombolysis In Myocardial, London Ambulance Service NHS Trust, London, United Kingdom
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large regional network of heart attack centers.METHODS
This was an observational cohort study to investigate
the relationship between thrombectomy use and
outcome after PPCI for STEMI. We merged the data-
bases of the 8 London Heart Attack Centres who
collect data based on the British Cardiac Intervention
Society (BCIS) dataset, with the analysis comparing
thrombectomy and no thrombectomy pre-speciﬁed.
The BCIS audit is part of a national mandatory audit
that all UK PCI centers participate in.
STUDY DATABASE. The UK BCIS audit collects data
from all hospitals in the United Kingdom that perform
PCI, recording information about every procedure
performed (13). PCI is deﬁned as the use of any cor-
onary device to approach, probe, or cross 1 or more
coronary lesions, with the intention of performing a
coronary intervention (13). The database is part of the
suite of datasets collected under the auspices of the
National Institute for Cardiovascular Outcomes
Research and is compliant with UK data protection
legislation. Data are collected prospectively at each
hospital, electronically encrypted, and transferred
online to a central database. Each patient entry offers
details of the patient journey, including the method
and timing of admission, inpatient investigations,
results, treatment, and outcomes. Patients’ survival
data are obtained by linkage of patients’ National
Health Service numbers to the Ofﬁce of National
Statistics, which records live status and the date of
death for all deceased patients.
POPULATION STUDY AND DESIGN. We examined an
observational cohort of consecutive patients with
STEMI treated with PPCI between January 2005
and July 2011 at all 8 tertiary cardiac centers in
London, United Kingdom. There are no other centers
in London that undertake PPCI. Patient and proce-
dural details were recorded at the time of the proce-
dure and during the admission into each center’s local
BCIS database. Anonymous datasets with linked
mortality data from the Ofﬁce of National Statistics; and the **Department of Cardiology, St. Thomas’
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577were merged for analysis from the 8 centers. During
the study period, 11,466 patients underwent PPCI. Of
these, 95.3% had complete datasets and National
Health Service numbers and were included in the
analysis (Figure 1).
All patients with onset of symptoms of <12 h and at
least 1-mm ST-segment elevation in 2 or more contig-
uous limb leads or at least 2 mm in 2 or more contig-
uous precordial leads or left bundle branch block
were considered for PPCI. Coronary angiography was
performed via the radial or femoral artery. The culprit
lesion was identiﬁed and crossed with an angioplasty
guidewire. Manual thrombus aspiration was per-
formed at the discretion of the operator followed by
conventional PCI to the culprit vessel.
THROMBUS ASPIRATION PROCEDURE. Patients were
classiﬁed into thrombus aspiration or non–thrombus
aspiration groups. The thrombus aspiration group
included all patients in whom thrombus aspiration
was attempted. All thrombus aspiration was per-
formed manually using the following devices: Ex-
port (Medtronic, Minneapolis, Minnesota) in 67.4%;
X-Sizer (ev3, Plymouth, Minnesota) in 3.9%; Pronto
(Vascular Solutions, Minneapolis, Minnesota) in
2.9%; TEC (Boston Scientiﬁc, Natick, Massachusetts)
in 6.4%; and others including Hunter (Innovative
Health Technologies), QuickCat (Spectranetics,
Colorado Springs, Colorado), Eliminate (Terumo,FIGURE 1 Flow Diagram of Study Patients
Flow diagram of study patients describing patient exclusions and
makeup of study population. PPCI ¼ primary percutaneous
coronary intervention.Somerset, New Jersey), and Rescue (Boston Scientiﬁc)
in 19.4%. No mechanical devices were included in the
analysis.
CLINICAL OUTCOMES. Patient clinical and demo-
graphic data, procedural characteristics, bleeding
complications, procedural complications, all-cause
in-hospital mortality, nonfatal MI, reintervention,
and stroke were recorded during the admission.
In-hospital major adverse cardiac events (MACE)
were deﬁned as death, myocardial infarction (new
pathologic Q waves in the distribution of the treated
coronary artery with an increase of creatine kinase-
myocardial band to $2 the reference value or signif-
icant rise in troponin biomarkers, stroke, and target
vessel revascularization. Procedural complications
recorded included MI, emergency coronary artery
bypass graft, arterial complications, aortic/coronary
dissection, side branch occlusion, and arrhythmia.
Following discharge, long-term all-cause mortality
was obtained by linkage to the Ofﬁce of National Sta-
tistics. Successful primary PCI result was deﬁned as
ﬁnal TIMI ﬂow grade 3 and residual stenosis <20% in
the infarct-related artery at the end of the procedure.
ETHICS. The data was collected as part of a national
cardiac audit and all patient identiﬁable ﬁelds were
removed prior to analysis. The local ethics committee
advised us that formal ethical approval was not
required.
STATISTICAL ANALYSIS. Clinical characteristics of
thrombus aspiration versus PCI-only treated patients
were compared using the Pearson chi-square test for
categorical variables and Student t test for continuous
variables. Normality of distribution was assessed us-
ing the Shapiro-Wilks test. We calculated Kaplan-
Meier product limits for cumulative probability of
reaching an endpoint and used the log-rank test for
evidence of a statistically signiﬁcant difference
between the groups. Time was measured from the
ﬁrst admission for a procedure to outcome (all-cause
mortality). Cox regression analysis was used to esti-
mate hazard ratios for the effect of thrombus aspira-
tion in age-adjusted and fully adjusted models, based
on covariates (p < 0.05) associated with the outcome.
The proportional hazards assumption was evaluated
by examining log(-log) survival curves and addition-
ally was tested with Schoenfeld residuals. The pro-
portional hazard assumption was satisﬁed for all
outcomes evaluated.
A propensity score analysis was carried out using
a nonparsimonious logistic regression model com-
paring thrombus aspiration and PCI-only patients.
Multiple variables were included in the model,
FIGURE 2 Percentage of Patients Undergoing Thrombectomy
Before PPCI From 2005 to 2011
The bar graph shows the percentage of patients undergoing
thrombectomy before PPCI from 2005 to 2011. PPCI ¼ primary
percutaneous coronary intervention.
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578including age, sex, diabetes, hypertension, hyper-
cholesterolemia, previous coronary artery bypass
graft, previous PCI, previous MI, multivessel disease,
chronic renal failure, pre-procedure TIMI ﬂow, ejec-
tion fraction, procedural success, and glycoprotein
IIb/IIIa use. The C-score was 0.78, indicating good
discrimination. After ranking propensity score in an
ascending order, a nearest neighbor 1:1 matching al-
gorithm was used with calipers of 0.2 SD of the logit
of the propensity score. Each thrombectomy and PCI-
only patient was used in at most 1 matched pair to
create a matched sample with similar distribution of
baseline characteristics between observed groups.
Based on the matched samples, the Cox proportional
hazard model was used to determine the impact of
thrombectomy on mortality over follow-up. STATA
(version 10, StataCorp, College Station, Texas) was
used for all analysis.
RESULTS
We included 10,929 patients in the study population
with a mean age of 62.25 years; 22.5% of the patients
were women. A total of 39.1% of the patients had
hypertension, 41.5% had dyslipidemia, 55.9% were
active or ex-smokers, and 15.2% had diabetes. In our
cohort, 6.4% of patients had poor left ventricular
function with 6.0% of patients presenting with
cardiogenic shock. The overwhelming majority of PCI
procedures were performed through the femoral
route, being the access route of choice for each study
year and accounting for 76.5% of procedures
throughout the study period. However, radial pro-
cedures did increase from <10% in 2005 to approxi-
mately 40% in 2011. In our cohort, 41.4% of patients
received a drug-eluting stent and 69.9% received a
glycoprotein IIb/IIIa inhibitor.
In our cohort, 3,572 patients (32.7%) underwent
thrombus aspiration during their PPCI (thrombus
aspiration group) and 7,357 (67.3%) did not (PCI-only
group). The percentage of patients who underwent
thrombectomy use quadrupled over the course of the
study period, from 7.6% in the ﬁrst year to 48.5% in
the last year (Figure 2).
PATIENT CHARACTERISTICS. Overall, the thrombus
aspiration group was younger, more likely to be male
and have poor left ventricular function compared
with the PCI-only group (Table 1). Higher rates of
previous MI, hypercholesterolemia, diabetes, and
renal failure were seen in the PCI-only group. No
differences were seen in the incidence of shock.
PROCEDURAL CHARACTERISTICS AND OUTCOMES.
There were no differences in the rates of multivesseldisease or multivessel intervention between the
groups (Table 2). There were higher rates of drug-
eluting stent and glycoprotein IIb/IIIa inhibitor use
in the thrombus aspiration group than in the PCI-only
group. Thrombus aspiration patients had signiﬁ-
cantly higher rates of infarct-related artery TIMI ﬂow
grade 0 (68.5% vs. 42.7%, p < 0.0001) and lower rates
of infarct-related artery TIMI ﬂow grade 3 (6.7% vs.
13.6%; p > 0.0001) at presentation compared with
those treated with PCI alone. Procedural success
rates deﬁned as rates of post-procedural TIMI ﬂow
grade 3 (thrombus aspiration 90.9% vs. PCI only
89.2%; p ¼ 0.005) were higher in the thrombus aspi-
ration group than in the PCI-only group.
IN-HOSPITAL OUTCOME. In-hospital MACE rates
were lower in the thrombus aspiration group than in
the PCI-only group (4.4% vs. 5.5%; p ¼ 0.012). There
was no difference in the incidence of cerebrovascular
accident between the 2 groups (Table 3).
LONG-TERM OUTCOME. Patients were followed-up
for a median of 3.0 years (interquartile range: 1.2 to
4.6 years). Kaplan-Meier analysis demonstrated that
there was no statistically signiﬁcant difference in
mortality rates between the 2 groups (14.8% aspira-
tion vs. 15.3% PCI-only; p ¼ 0.737) (Figure 3).
PREDICTORS OF ALL-CAUSE MORTALITY. Age-adjusted
Cox analysis revealed that the use of thrombectomy
in PPCI was not associated with all-cause mortality
(hazard ratio [HR]: 0.77, 95% conﬁdence interval [CI]:
0.65 to 1.10) (Figure 4). This did not change after
TABLE 1 Baseline Characteristics According to Thrombus Aspiration or PCI-Only Group
Thrombus
Aspiration
(n ¼ 3,572)
PCI Only
(n ¼ 7,357) p Value
Data
Completeness,
% (n)
(n ¼ 10,929)
Age, yrs 60.80  13.17 62.96  13.25 <0.0001 100 (10,929)
Female 758 (21.2) 1,698 (23.1) 0.026 99.8 (10,905)
Previous MI 426 (11.9) 1315 (17.9) <0.0001 91.8 (10,030)
Previous CABG 92 (2.6) 236 (3.2) 0.057 95.5 (10,432)
Previous PCI 454 (12.7) 864 (11.7) 0.246 95.1 (10,390)
Hypercholesterolemia 1,454 (40.7) 3,081 (41.9) 0.039 94.6 (10,344)
Diabetes mellitus 502 (14.1) 1,159 (15.8) 0.005 94.0 (10,273)
Hypertension 1,383 (38.7) 2,894 (39.3) 0.143 94.6 (10,344)
Smoking history 2,135 (59.8) 3,974 (54.0) 0.030 85.9 (9,393)
PVD 55 (1.5) 138 (1.9) 0.190 94.6 (10,344)
CKD (Creat >200), mmol/l 22 (0.6) 75 (1.0) 0.018 88.9 (9,715)
Previous CVA 68 (1.9) 140 (1.9) 0.938 94.6 (10,344)
Left ventricular function <0.0001 39.8 (4,347)
Good 604 (16.9) 2,179 (29.6)
Fair 406 (11.4) 456 (6.2)
Poor 288 (8.1) 414 (5.6)
Cardiogenic shock 234 (6.6) 422 (5.7) 0.100 98.3 (10,748)
Direct transfer 2,316 (64.8) 4,080 (55.5) <0.0001 91.2 (9,971)
Call-to-balloon time, min 115 (92, 165) 125 (98, 170) 0.057 61.0 (6,161)
Door-to-balloon time, min 45 (26, 120) 48 (26, 118) 0.191
Values are mean  SD, n (%), or median (interquartile range).
CABG ¼ coronary artery bypass graft; CKD ¼ chronic kidney disease; Creat ¼ creatinine concentration;
CVA ¼ cardiovascular accident; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention;
PVD ¼ pulmonary vascular disease.
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579multivariate adjustment (HR: 0.89, 95% CI: 0.70 to
1.23) (Figure 5). The variables that showed indepen-
dent association with mortality were age, chronic
kidney disease, severe systolic left ventricular
impairment, cardiogenic shock, multivessel disease,
and call-to-balloon time (Figure 4). Radial artery ac-
cess, TIMI ﬂow grade 3 in the infarct-related artery
prior to PPCI, procedural success, and use of a
glycoprotein IIb/IIa inhibitor were independently
associated with 3-year survival.
The preceding Cox proportional hazard model was
repeated with the year of procedure included as a
categorical variable to allow for improvements in PCI
technique and technology over the long study period.
This conﬁrmed no association between thrombec-
tomy use and mortality (HR: 0.85, 95% CI: 0.63 to
1.12).
PROPENSITY SCORE. To further account for con-
founding variables and bias, propensity score
matching was performed to adjust for differences in
demographic and procedural variables producing a
total of 6,912 patients (3,456 in the thrombus aspira-
tion group and 3,456 in the PCI-alone group).
Following matching, the baseline demographics and
procedural variables were well balanced in the 2
propensity-matched cohorts. In the propensity-
matched cohorts, Cox regression analysis revealed
that the use of thrombectomy during PPCI was not a
predictor of all-cause mortality (HR: 0.82, 95% CI:
0.60 to 1.13).DISCUSSION
In this large observational study of 10,929 patients
undergoing PPCI for STEMI, 32.7% of patients un-
derwent thrombus aspiration during PPCI. Despite a
greater rate of procedural success and lower in-
hospital MACE, in-hospital mortality and long-term
survival were similar for the patients who under-
went thrombus aspiration to those who received PCI
only. Our data suggest that in our cohort routine
thrombus aspiration during PPCI, compared with not
receiving therapy, does not appear to be associated
with a reduction in mortality rates. This is the largest
cohort of PPCI-treated STEMI patients to have
demonstrated no association between thrombus
aspiration and reduced mortality.
Studies assessing the use of thrombectomy and
outcome have demonstrated varied results. Cur-
rent European Society of Cardiology and American
College of Cardiology/American Heart Association
guidelines recommend thrombus aspiration as an
adjunctive therapy during PPCI (4,5). These IIarecommendations are based predominately on the
TAPAS study, which demonstrated an approximately
50% reduction in mortality at 1 year (6,7). However,
the TAPAS trial (6,7) is the only randomized trial to
have demonstrated a signiﬁcant beneﬁcial effect on
mortality, and TAPAS was not designed or powered
for the primary endpoint of mortality with subse-
quent data from observational studies also suggesting
beneﬁt (3). Although our results may be consistent
with more recent interventional studies such as
TASTE (11,12) (that imply that routine thrombectomy
use may not be associated with an improvement in
mortality), we feel that at present there is insufﬁcient
data to exclude thrombectomy as a potentially effec-
tive therapy during PPCI, even after considering our
observational data. To date, most studies have been
underpowered, not selective enough in recruitment or
have not included sensitive enough endpoints to
detect a clinically meaningful beneﬁt. Although the
TASTE study was a large multicenter, prospective,
randomized controlled trial that randomized 7,244
patients undergoing PPCI to either manual thrombus
aspiration or no aspiration, the study does have limi-
tations. This was a novel trial design using an estab-
lished national registry. The study had a primary
endpoint of mortality but did not reliably collect TIMI
TABLE 3
to Throm
In-hospita
MACE
Death
Q wave
Reinterv
CVA
Emerge
Arterial co
Values are n
MACE ¼
TABLE 2 Procedural Characteristics According to Thrombus Aspiration or
PCI-Only Group
Thrombus
Aspiration
(n ¼ 3,572)
PCI Only
(n ¼ 7,357) p Value
Data
Completeness
(n ¼ 10,929)
Access 98.2 (10,728)
Femoral 2,425 (67.9) 5,931 (80.6) <0.0001
Radial 1,148 (32.1) 1,303 (17.7) <0.0001
No. of diseased vessels 94.4 (10,313)
Single-vessel 1,593 (68.0) 3,493 (63.0) 0.320
Multivessel 1,685 (47.2) 3,542 (48.1) 0.320
Mean vessels 1.67  1.0 1.68  1.0 0.721
Target vessel 100% (10,929)
Right coronary artery 1,557 (43.6) 2,889 (39.3) <0.0001
Left main coronary artery 50 (1.4) 137 (1.9) 0.086
Left anterior descending 661 (18.5) 1831 (24.9) <0.0001
Left circumﬂex coronary 467 (13.1) 1,293 (17.6) <0.0001
Saphenous vein graft 68 (1.9) 122 (1.7) 0.351
Multivessel intervention 1,979 (55.4) 3,864 (52.5) 0.320 94.4% (10,313)
Vessel diameter 3.92  7.6 3.89  26.68 0.712 86.7% (9,473)
Vessel length 21.95  9.3 22.91  11.55 <0.0001 86.7% (9,473)
TIMI Pre-angiography <0.0001 84.8% (9,266)
TIMI ﬂow grade 0 2,447 (68.5) 3,141 (42.7)
TIMI ﬂow grade 3 239 (6.7) 1,001 (13.6)
DES 1,687 (47.2) 2,841 (38.6) <0.0001 95.5% (10,433)
GP IIb/IIIa inhibitor 2,836 (79.4) 4,806 (65.3) <0.0001 95.5% (10,433)
Procedural success 3,247 (90.9) 6,560 (89.2) 0.005 84.8% (9,266)
Values are n (%), mean  SD, or % (n).
DES ¼ drug-eluting stent(s); GP ¼ glycoprotein; PCI ¼ percutaneous coronary intervention; TIMI ¼ Throm-
bolysis In Myocardial Infarction.
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580ﬂow grade, myocardial blush, and ST-segment reso-
lution, which may be related to improved clinical
outcomes. In addition, other potentially important
endpoints such as heart failure or recurrent MI were
either not collected or reliably captured as would have
occurred in a conventional randomized controlled
trial. Also, approximately 7% of patients were not
randomized because the clinicians felt thrombusIn-Hospital Outcomes and Complications Post-PCI According
bus Aspiration or PCI-Only Group
Thrombus
Aspiration
(n ¼ 3,572)
PCI Only
(n ¼ 7,357) p Value
Data
Completeness
(n ¼ 10,929)
l 96.5% (10,545)
157 (4.4) 408 (5.5) 0.012
93 (2.6) 219 (3.0) 0.423
MI 54 (1.5) 140 (1.9) 0.216
ention PCI 11 (0.3) 40 (0.5) 0.135
14 (0.4) 14 (0.2) 0.065
ncy CABG 6 (0.2) 30 (0.4) 0.055
mplications 28 (0.8) 58 (0.7) 0.914 88.3% (9,648)
(%) or % (n).
major adverse cardiac events; other abbreviations as in Table 1.aspiration was required and the expected event rate
(30-day mortality) was signiﬁcantly lower (3%) than
had been estimated (6.3%) for the power calculation,
implying the study was underpowered. Perhaps not
surprisingly, therefore, the TASTE study demon-
strated no signiﬁcant difference in either 30-day or
more recently 1-year mortality between the 2 groups
(11,12).
Other studies such as the INFUSE-AMI (Intra-
coronary Abciximab and Aspiration Thrombectomy in
Patients with Large Anterior Myocardial Infarction)
randomized trial (14) have come to similar conclu-
sions as thrombus aspiration was not effective in
reducing infarct size. These trials are consistent with
meta-analyses (9,15) that again suggest no mortality
beneﬁt with thrombectomy. Although our data
appear to support the conclusion that aspiration
thrombectomy does not improve mortality, we feel
that our results merely support the conclusion at
present that there have been insufﬁciently powered
or appropriately designed trials to detect or exclude
clinically important beneﬁts.
Thrombectomy use in our cohort was shown to
increase over the study period with a sharp increase
following the publication of TAPAS in 2008.
However, none of the participating centers in our
cohort had local guidelines dictating when to use a
thrombus aspiration catheter and, therefore, there
was likely to be a heterogeneous mix of cases. As
thrombus characteristics and composition vary ac-
cording to the type of acute coronary syndromes and
time to presentation, it is likely that different sub-
sets of acute coronary syndrome patients may
respond differently to thrombus aspiration. As our
database does not have detailed morphological
characterization of lesion and thrombus morphology
or thrombus burden, we are unable to explore
whether there are subsets of patients who may
respond better than others to aspiration. In addition,
it has been suggested that thrombus aspiration may
not be a risk-free procedure. Systemic embolization
may occur, and in a recent meta-analysis, thrombus
aspiration was associated with a trend toward an
increased rate of stroke (p ¼ 0.06) (10). Although
in our cohort, there was no signiﬁcant difference
between the groups in the rates of stroke and
neurological complications, it is possible that some
subsets of patients (perhaps with established orga-
nized thrombus) may not only not beneﬁt from
aspiration but could be harmed by the risk of
embolization, either into the distal coronary bed or
indeed systemically.
We found that thrombus aspiration was less likely
to be performed in older patients perhaps due to a
FIGURE 3 Kaplan-Meier Curves Showing All-Cause Mortality After PCI
Kaplan-Meier curves showing cumulative probability of all-cause mortality after PCI
according to group. LR ¼ log-rank; PCI ¼ percutaneous coronary intervention.
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581higher incidence of features known to reduce the
likelihood of successful delivery of the thrombectomy
catheter (16), including greater vessel tortuosity and
calciﬁcation. In addition, we found patients with pre-
PPCI TIMI ﬂow grade 2 or 3 were less likely to un-
dergo thrombus aspiration. This is probably due to a
lower visible thrombus burden in these patients
compared with those with pre-PPCI TIMI ﬂow grade
0 or 1 and may be appropriate. However, this varia-
tion in use of thrombus extraction in different
settings of PPCI may well hide an important beneﬁt
that is only seen in certain subsets of patients.
Although we did not ﬁnd a signiﬁcant interaction
between pre-PPCI TIMI ﬂow grade and the impact of
thrombectomy on mortality, by analyzing these sub-
sets, we are further decreasing the power to detect a
potentially important signal and so this data should
be interpreted with caution.
It is generally accepted that distal embolization
plays a pivotal role in causing microvascular injury
after PPCI (2,17) with a high thrombus burden asso-
ciated with increased incidence of distal embolization
and higher frequency of adverse outcomes (MACE
and mortality) (18). Thrombectomy devices wereFIGURE 4 Age-Adjusted Cox Regression Analysis for Hazard of All-
Variable Hazard Ratio (95% CI)
)80.1-60.1(70.1egA
Sex (Male)
Ethnicity (South Asian) 1.17 (0.93-1.47)
Diabetic 1.63 (1.42-1.88)
Previous MI 1.44 (1.26-1.66)
Previous CABG 1.84 (1.44-2.37)
Previous PCI 1.34 (1.15-1.58)
Hypertension 1.01 (0.89-1.13)
Hypercholesterolemia
TIMI 3 flow pre-procedure 0.78 (0.59-0.98)
)24.3-83.1(71.2DKC
Ejection Fraction <30% 2.11 (1.71-2.59)
GP IIb/IIIa use 0.62 (0.55-0.69)
Procedural Success 0.47 (0.40-0.54)
Access (Radial) 0.66 (0.56-0.77)
Cardiogenic Shock 5.21 (4.48-6.05)
Multivessel Disease 1.63 (1.44-1.83)
Call to Balloon Time 1.04 (1.02-1.07)
Thrombus Aspiration 0.77 (0.65-1.10)
Hazard ratios after age-adjusted analysis 
1.81 (1.60-2.03)
1.39 (1.24-1.57)
Age-adjusted Cox regression analysis for hazard of all-cause mortality af
interval; GP ¼ glycoprotein; MI ¼ myocardial infarction; TIMI ¼ Thrombintroduced to reduce thrombus burden and prevent
distal embolization, thereby increasing microvascular
ﬂow with a hope to improve outcomes, which intui-
tively is a good intervention to undertake (19,20).Cause Mortality After PPCI
ter PPCI. CABG ¼ coronary artery bypass graft; CKD ¼ chronic kidney disease; CI ¼ conﬁdence
olysis In Myocardial Infarction; other abbreviations as in Figures 1 and 3.
FIGURE 5 Multivariate Cox Regression Analysis for Hazard of All-Cause Mortality After PPCI
Variable
1.07 (1.05-1.08)Age
3.90 (1.59-5.19)
Sex (Male)
Diabetic 1.41 (1.02-1.93)
Previous MI 1.10 (0.76-1.58)
Previous CABG 1.23 (0.69-2.19)
Previous PCI 1.45 (0.71-1.85)
Hypercholesterolemia
TIMI 3 flow pre-procedure 0.80 (0.69-0.94)
Ejection Fraction <30% 2.39 (1.75-3.27)
GP IIb/IIIa use 0.70 (0.54-0.91)
Procedural success 0.65 (0.46-0.93)
Access (Radial) 0.84 (0.65-0.94)
Cardiogenic Shock 4.14 (2.92-5.83)
Multivessel Disease 1.68 (1.28-2.21)
Call to Balloon Time 1.02 (1.01-1.03)
Thrombus aspiration 0.89 (0.70-1.23)
Hazard ratios after multivariate analysis
0 1 2 3 4 5 6
Hazard Ra o
CKD
Hazard Ratio (95% CI)
1.14 (0.87-1.49)
1.12 (0.84-1.49)
Multivariate Cox regression analysis for hazard of all-cause mortality after PPCI. Abbreviations as in Figures 1, 3, and 4.
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582Theoretically, thrombectomy appears to be a valuable
approach to improve outcomes after PPCI. In this
study, improved procedural outcomes and in-hospital
MACE rates with manual thrombectomy were seen;
however, these improvements were not associated
with a long-term mortality beneﬁt. Similar beneﬁts
on surrogate markers of reperfusion and clinical
outcomes with thrombectomy use have been
demonstrated in many randomized trials (21–24) and
meta-analyses (8,10,25,26). However, these have
often not translated into improved hard endpoints
such as mortality, and in the largest randomized
controlled trial performed to date (TASTE), thrombus
aspiration did not result in improved clinical out-
comes (11,12).
Our conclusion is that to date there has been no
sufﬁciently powered trial to answer this important
question. Despite our large cohort, we do not feel it is
sufﬁciently large to make a clear statement about the
lack of association of thrombus aspiration on mor-
tality. The TOTAL (A Randomized Trial of Routine
Aspiration Thrombectomy With PCI Versus PCI Alone
in Patients With STEMI Undergoing Primary PCI)
study is now recruiting, and this study will recruit
10,000 patients and has a combined endpoint of car-
diovascular death, MI, shock, and heart failure. Thisstudy is also powered assuming a 5% to 7% crossover
rate and hence is more effectively designed to
establish the clinical efﬁcacy of aspiration catheters
in PPCI.
STRENGTHS AND LIMITATIONS OF THIS STUDY.
The strength of this study is that it includes patients
from 8 different centers in a large metropolitan city
with a diverse ethnic and social makeup. The study
includes patients with cardiogenic shock, previous
bypass surgery, and other comorbidities and is thus
representative of the broad range of patients
encountered in day-to-day clinical practice. Whereas
inclusion of such patients may result in bias, the
baseline characteristics were similar and any differ-
ences were adjusted for in the multivariate analyses.
To further account for confounding variables and
bias, propensity analyses were performed, which
were in agreement with ﬁndings from other cohort
analyses. Mortality tracking in England is particu-
larly robust based on ofﬁcial UK Ofﬁce of National
Statistics data and hence our mortality endpoint is
reliable. The multivariate analyses highlight the
quality of the data with well-recognized predictors
of mortality associated with adverse outcomes in our
dataset.
PERSPECTIVES
Device-based removal of thrombus from the infarct-related
artery (adjunctive thrombectomy) during PPCI for STEMI
has been the object of increasing interest, but it is currently
unclear whether a survival beneﬁt is associated with the
therapy. We found that despite greater rates of procedural
success and lower rates of in-hospital MACE, in-hospital
mortality and long-term survival were similar for the patients
who underwent thrombus aspiration to those who received PCI
only. Our data suggest that in our cohort routine thrombus
aspiration during PPCI, compared with not receiving therapy,
does not appear to be associated with a reduction in mortality
rates. We feel that our results support the conclusion that to
date there have been insufﬁciently powered or few appropri-
ately designed trials to detect or exclude clinically important
beneﬁts of thrombus aspiration and that there is an increasing
need for these studies.
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583However, our study also has limitations. First,
our study only applies to patients with STEMI
who received PPCI. In addition, this study has all
the limitations of a registry and all the potential
bias and unmeasured confounding associated with
nonrandomized studies. In addition, we cannot
exclude the possibility of under-reporting of com-
plications, although the tracking of mortality is
robust and we only included the 95.3% of patients
who had deﬁnitive mortality data in our study
cohort. Despite the very large size of our population
studied, our cohort does not have the power to
detect a small but important difference in mortality
related to thrombectomy use. While awaiting the
results of the TOTAL trial and the meta-analyses
that will follow, it would be useful to have data
from large national level registries that may have
the power to describe potentially important associ-
ation of thrombus aspiration with clinical beneﬁts.
This will include identifying high-risk individuals
such as those with high thrombus burden who
remain more likely to beneﬁt from thrombectomy
use.
CONCLUSIONS
In this large registry of nearly 11,000 patients, routine
thrombus aspiration does not appear to be associ-
ated with reduced long-term mortality in patientsundergoing PPCI, although procedural success and
in-hospital MACE were improved.
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